Alimera Sciences Inc.

10.30+0.0200+0.19%Vol 3.82K1Y Perf 123.91%
Jun 15th, 2021 16:00 DELAYED
BID10.22 ASK10.30
Open10.36 Previous Close10.28
Pre-Market- After-Market-
 - -  - -%
Target Price
16.00 
Analyst Rating
Strong Buy 1.00
Potential %
55.34 
Finscreener Ranking
★★★★+     56.51
Insiders Trans % 3/6/12 mo.
-100/-100/- 
Value Ranking
★★★★     55.49
Insiders Value % 3/6/12 mo.
-100/-100/-35 
Growth Ranking
★★★★     59.53
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-14 
Income Ranking
 —    -
Market Cap71.23M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
76.87 
Earnings Date
4th Aug 2021

Today's Price Range

10.0910.41

52W Range

3.8212.25

5 Year PE Ratio Range

-2.205.80

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-0.29%
1 Month
20.19%
3 Months
-5.16%
6 Months
146.41%
1 Year
123.91%
3 Years
-20.16%
5 Years
-57.87%
10 Years
-91.25%

TickerPriceChg.Chg.%
ALIM10.300.02000.19
AAPL129.64-0.8400-0.64
GOOG2 520.66-6.3800-0.25
MSFT258.36-1.5300-0.59
XOM64.332.26003.64
WFC45.460.31000.69
JNJ164.49-0.8800-0.53
FB336.75-0.0200-0.01
GE13.540.07000.52
JPM155.18-2.3900-1.52
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.50-0.63-26.00
Q04 2020-0.09-0.18-100.00
Q03 2020-0.49-0.1275.51
Q02 2020-2.14-0.5176.17
Q01 2020-0.43-0.2444.19
Q04 2019-0.370.08121.62
Q03 2019-0.60-0.600.00
Q02 2019-0.60-1.05-75.00
Earnings Per EndEstimateRevision %Trend
6/2021 QR1.25725.00Positive
9/2021 QR-0.110.00-
12/2021 FY0.62219.23Positive
12/2022 FY-0.06--
Next Report Date4th Aug 2021
Estimated EPS Next Report1.25
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume3.82K
Shares Outstanding6.92M
Trades Count38
Dollar Volume641.91K
Avg. Volume67.49K
Avg. Weekly Volume12.56K
Avg. Monthly Volume15.29K
Avg. Quarterly Volume44.49K

Alimera Sciences Inc. (NASDAQ: ALIM) stock closed at 10.3 per share at the end of the most recent trading day (a 0.19% change compared to the prior day closing price) with a volume of 3.82K shares and market capitalization of 71.23M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 127 people. Alimera Sciences Inc. CEO is Richard S. Eiswirth.

The one-year performance of Alimera Sciences Inc. stock is 123.91%, while year-to-date (YTD) performance is 144.08%. ALIM stock has a five-year performance of -57.87%. Its 52-week range is between 3.82 and 12.25, which gives ALIM stock a 52-week price range ratio of 76.87%

Alimera Sciences Inc. currently has a PE ratio of -7.20, a price-to-book (PB) ratio of 12.98, a price-to-sale (PS) ratio of 1.31, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -7.78%, a ROC of -% and a ROE of 10.18%. The company’s profit margin is -6.66%, its EBITDA margin is 7.00%, and its revenue ttm is $54.39 Million , which makes it $7.87 revenue per share.

Of the last four earnings reports from Alimera Sciences Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $1.25 for the next earnings report. Alimera Sciences Inc.’s next earnings report date is 04th Aug 2021.

The consensus rating of Wall Street analysts for Alimera Sciences Inc. is Strong Buy (1), with a target price of $16, which is +55.34% compared to the current price. The earnings rating for Alimera Sciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Alimera Sciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Alimera Sciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 20.91, ATR14 : 0.42, CCI20 : 56.46, Chaikin Money Flow : 0.46, MACD : 0.21, Money Flow Index : 45.48, ROC : 2.49, RSI : 55.17, STOCH (14,3) : 68.75, STOCH RSI : 0.69, UO : 65.11, Williams %R : -31.25), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Alimera Sciences Inc. in the last 12-months were: C. Daniel Myers (Sold 5 000 shares of value $33 650 ), Philip Ashman (Buy at a value of $5 922), Philip Ashman (Sold 45 shares of value $433 ), Richard S. Eiswirth (Buy at a value of $10 377)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Alimera Sciences Inc.

Alimera Sciences is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN(R) is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. A $2B global market, DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema leading to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology.

CEO: Richard S. Eiswirth

Telephone: +1 678 990-5740

Address: 6120 Windward Parkway, Alpharetta 30005, GA, US

Number of employees: 127

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

62%38%

Bearish Bullish

65%35%

News

Stocktwits